CAR 509
Alternative Names: CAR-509Latest Information Update: 28 Oct 2022
Price :
$50 *
At a glance
- Originator Carmel Biosciences
- Class Cardiovascular therapies
- Mechanism of Action Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 28 Oct 2022 No recent reports of development identified for preclinical development in Metabolic-disorders in USA
- 26 Sep 2018 Preclinical trials in Cardiovascular disorders in USA (unspecified route) prior to September 2018